Growth at 2 years of age in HIV-exposed uninfected children in the United States by trimester of maternal antiretroviral initiation

Pediatric Infectious Disease Journal

Volumn 36, Issue 2, 2017, Pages 189-197

  Jacobson, Denise L ^a   Patel, Kunjal ^a,b   Williams, Paige L ^a,b   Geffner, Mitchell E ^c   Siberry, George K ^d   DiMeglio, Linda A ^e   Crain, Marilyn J ^f   Mirza, Ayesha ^g   Chen, Janet S ^h   McFarland, Elizabeth ^i,x   Kacanek, Deborah ^a   Silio, Margarita ^j   Rich, Kenneth ^k   Borkowsky, William ^l,r   Van Dyke, Russell B ^j,v   Miller, Tracie L ^m   Shearer, William ⁿ   Paul, Mary ⁿ   Cooper, Norma ⁿ   Harris, Lynette ⁿ   Purswani, Murli ^o   Stuard, Emma ^o   Cintron, Anna ^o   Puga, Ana ^p   Cooley, Dia ^p   Patton, Doyle ^p   Leon, Deyana ^p   Yogev, Ram ^q   Sanders, Margaret Ann ^q   Malee, Kathleen ^q   Hunter, Scott ^q   Deygoo, Sandra ^r   Rozelman, Helen ^r   Knapp, Katherine ^s   Allison, Kim ^s   Wilkins, Megan ^s   Acevedo Flores, Midnela ^t   Angeli Nieves, Lourdes ^t   Olivera, Vivian ^t   Mendez, Hermann ^u   Dennie, Ava ^u   Bewley, Susan ^u   Craig, Karen ^v   Sirois, Patricia ^v   Beatty, Newana ^f   Huldtquist, Julie ^f   Spector, Stephen ^w   Manning, Jean ^w   Nichols, Sharon ^w   Barr, Emily ^x   McEvoy, Robin ^x   Rathore, Mobeen ^g   Stowers, Kristi ^g   Usitalo, Ann ^g   Richardson, Lourdes ^k   Turpin, Delmyra ^k   Smith, Renee ^k   Dieudonne, Arry ^y   Bettica, Linda ^y   Adubato, Susan ^y   Scott, Gwendolyn ^m   Florez, Claudia ^m   Willen, Elizabeth ^m   Frederick, Toinette ^z   Davtyan, Mariam ^z   Mejia, Maribel ^z   Rodriguez, Zoe ^aa   Heyer, Ibet ^aa   Trifilio, Nydia Scalley ^aa   more..

^a CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF FLORIDA   (United States)

^h DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

ⁱ CHILDREN S HOSPITAL   (United States)

^j TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^l NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^m UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

ⁿ BAYLOR COLLEGE OF MEDICINE   (United States)

^o BRONX LEBANON HOSPITAL CENTER   (United States)

^p Children's Diagnostic and Treatment Center   (United States)

^q Ann and Robert H Lurie Children's Hospital of Chicago   (United States)

^r NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^s ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^t San Juan City Community Oncology Program   (United States)

^u SUNY DOWNSTATE MEDICAL CENTER   (United States)

^v TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^w UNIVERSITY OF CALIFORNIA   (United States)

^x UNIVERSITY OF COLORADO   (United States)

^y UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^z UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^aa UNIVERSITY OF PUERTO RICO   (Puerto Rico)

more..

Author keywords

Early childhood growth; HIV exposed uninfected children; Maternal antiretroviral therapy; Obesity; Tenofovir; Trimester of pregnancy

Indexed keywords

ABACAVIR; ATAZANAVIR; CD4 ANTIGEN; DIDANOSINE; EMTRICITABINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; RITONAVIR; TENOFOVIR; ZIDOVUDINE; ANTIRETROVIRUS AGENT;

ADULT; ANTHROPOMETRY; ANTIRETROVIRAL THERAPY; ARTICLE; BLACK PERSON; BODY HEIGHT; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CHILD; CHILD GROWTH; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; FIRST TRIMESTER PREGNANCY; HEAD CIRCUMFERENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MATERNAL DISEASE; OUTCOME ASSESSMENT; PREGNANCY; PRENATAL DRUG EXPOSURE; PRESCHOOL CHILD; PRIORITY JOURNAL; SECOND TRIMESTER PREGNANCY; SKINFOLD; UNITED STATES; VIRUS LOAD; CHILD DEVELOPMENT; MATERNAL EXPOSURE; MOTHER; PHYSIOLOGY; PROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; TIME TO TREATMENT;

ADULT; ANTI-RETROVIRAL AGENTS; BODY HEIGHT; BODY WEIGHT; CHILD DEVELOPMENT; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; MATERNAL EXPOSURE; MOTHERS; PROSPECTIVE STUDIES; TIME-TO-TREATMENT;

EID: 84992745690     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000001387     Document Type: Article

References (38)

1. World Health Organization. Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants: Toward Universal Access (2010 version). 2010. World Health Organization, Geneva.
2. Adams Waldorf KM, McAdams RM. Influence of infection during pregnancy on fetal development. Reproduction. 2013;146:R151-R162.
3. Jauniaux E, Nessmann C, Imbert MC, et al. Morphological aspects of the placenta in HIV pregnancies. Placenta. 1988;9:633-642.
4. Vermaak A, Theron GB, Schubert PT, et al. Morphologic changes in the placentas of HIV-positive women and their association with degree of immune suppression. Int J Gynaecol Obstet. 2012;119:239-243.
5. Ross AC, Leong T, Avery A, et al. Effects of in utero antiretroviral exposure on mitochondrial DNA levels, mitochondrial function and oxidative stress. HIV Med. 2012;13:98-106.
6. Barker DJ, Fall CH. Fetal and infant origins of cardiovascular disease. Arch Dis Child. 1993;68:797-799.
7. Eriksson JG, Forsén T, Tuomilehto J, et al. Catch-up growth in childhood and death from coronary heart disease: longitudinal study. BMJ. 1999;318:427-431.
8. Newell ML, Borja MC, Peckham C; European Collaborative Study. Height, weight, and growth in children born to mothers with HIV-1 infection in Europe. Pediatrics. 2003;111:e52-e60.
9. Powis KM, Smeaton L, Ogwu A, et al. Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in Botswana. J Acquir Immune Defic Syndr. 2011;56:131-138.
10. Heidari S, Mofenson L, Cotton MF, et al. Antiretroviral drugs for preventing mother-to-child transmission of HIV: a review of potential effects on HIV-exposed but uninfected children. J Acquir Immune Defic Syndr. 2011;57:290-296.
11. Ransom CE, Huo Y, Patel K, et al; P1025 Team of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group. Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy. J Acquir Immune Defic Syndr. 2013;64:374-381.
12. Siberry GK, Williams PL, Mendez H, et al; Pediatric HIV/AIDS Cohort Study (PHACS). Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS. 2012;26: 1151-1159.
13. Gibb DM, Kizito H, Russell EC, et al; DART trial team. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Med. 2012;9:e1001217.
14. Viganò A, Mora S, Giacomet V, et al. In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIVuninfected children born to HIV-infected mothers. Antivir Ther. 2011;16:1259-1266.
15. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915-920.
16. Danaei G, Tavakkoli M, Hernán MA. Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol. 2012;175:250-262.
17. Jacobson DL, Patel K, Siberry GK, et al; Pediatric HIV/AIDS Cohort Study. Body fat distribution in perinatally HIV-infected and HIV-exposed but uninfected children in the era of highly active antiretroviral therapy: outcomes from the Pediatric HIV/AIDS Cohort Study. Am J Clin Nutr. 2011;94:1485-1495.
18. National Health and Nutrition Examination Survey. Anthropometry Procedures Manual. 2002. CDC/National Center for Health Statistics, Atlanta.
19. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Adv Data. 2000:1-27.
20. Fenton TR, Sauve RS. Using the LMS method to calculate z-scores for the Fenton preterm infant growth chart. Eur J Clin Nutr. 2007;61:1380-1385.
21. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med. 2002;346:1863-1870.
22. Hernán MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19:766-779.
23. Williams PL, Seage GR 3rd, Van Dyke RB, et al; Pediatric HIV/AIDS Cohort Study. A trigger-based design for evaluating the safety of in utero antiretroviral exposure in uninfected children of human immunodeficiency virus-infected mothers. Am J Epidemiol. 2012;175:950-961.
24. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1:43-46.
25. Textor J, Hardt J, Knüppel S. DAGitty: a graphical tool for analyzing causal diagrams. Epidemiology. 2011;22:745.
26. Barker DJ. The origins of the developmental origins theory. J Intern Med. 2007;261:412-417.
27. Ogden CL, Carroll MD, Kit BK, et al. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014;311:806-814.
28. Ong KK, Dunger DB. Birth weight, infant growth and insulin resistance. Eur J Endocrinol. 2004;151(suppl 3):U131-U139.
29. Miller TL, Easley KA, Zhang W, et al; Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group; National Heart, Lung, and Blood Institute, Bethesda, MD. Maternal and infant factors associated with failure to thrive in children with vertically transmitted human immunodeficiency virus-1 infection: the prospective, P2C2 human immunodeficiency virus multicenter study. Pediatrics. 2001;108:1287-1296.
30. Vähäkangas K, Myllynen P. Drug transporters in the human blood-placental barrier. Br J Pharmacol. 2009;158:665-678.
31. Govindarajan R, Bakken AH, Hudkins KL, et al. In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta. Am J Physiol Regul Integr Comp Physiol. 2007;293:R1809-R1822.
32. MacFarland A, Abramovich DR, Ewen SW, et al. Stage-specific distribution of P-glycoprotein in first-trimester and full-term human placenta. Histochem J. 1994;26:417-423.
33. Anuurad E, Bremer A, Berglund L. HIV protease inhibitors and obesity. Curr Opin Endocrinol Diabetes Obes. 2010;17:478-485.
34. Fisher M, Moyle GJ, Shahmanesh M, et al; SWEET (Simplification With Easier Emtricitabine Tenofovir) group UK. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2009;51:562-568.
35. Sun M, Kingdom J, Baczyk D, et al. Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. Placenta. 2006;27:602-609.
36. Meyer zu Schwabedissen HE, Jedlitschky G, Gratz M, et al. Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. Drug Metab Dispos. 2005;33: 896-904.
37. Fiore S, Newell ML, Trabattoni D, et al. Antiretroviral therapy-associated modulation of Th1 and Th2 immune responses in HIV-infected pregnant women. J Reprod Immunol. 2006;70:143-150.
38. Watts DH, Williams PL, Kacanek D, et al; Pediatric HIV/AIDS Cohort Study. Combination antiretroviral use and preterm birth. J Infect Dis. 2013;207:612-621.